PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D growth 50-75% of AGEN's 25.62%. Bruce Berkowitz would examine spending effectiveness.
12.93%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
5.37%
Other expenses growth less than half of AGEN's 111.48%. David Dodd would verify if advantage is sustainable.
14.34%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
14.34%
Similar total costs growth to AGEN's 16.61%. Walter Schloss would investigate norms.
No Data
No Data available this quarter, please select a different quarter.
5.37%
D&A growth less than half of AGEN's 18.49%. David Dodd would verify if efficiency is sustainable.
-16.61%
EBITDA decline while AGEN shows 45.76% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-14.34%
Operating income decline while AGEN shows 32.62% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-295.23%
Other expenses reduction while AGEN shows 40.36% growth. Joel Greenblatt would examine advantage.
-20.40%
Pre-tax income decline while AGEN shows 34.53% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Net income decline while AGEN shows 34.53% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-19.61%
EPS decline while AGEN shows 38.80% growth. Joel Greenblatt would examine position.
-20.61%
Diluted EPS decline while AGEN shows 38.80% growth. Joel Greenblatt would examine position.
0.76%
Share count reduction exceeding 1.5x AGEN's 6.97%. David Dodd would verify capital allocation.
No Data
No Data available this quarter, please select a different quarter.